Although EpCAM is attractive for targeted cancer therapy, the fact that EpCAM is expressed also on normal epithelium, though to a much lower level, is a concern for potential on-target/off-tumor toxicity of targeted therapy against EpCAM-positive tumors. The gene discussed is EPCAM; the disease is cancer.